RhoVac's Prostate Cancer Drug Candidate, RV001, is granted Fast Track Designation by the FDA
RhoVac, a clinical stage company announced that the American FDA has granted Fast Track Designation to the company's drug candidate, RV001. Fast
Latest News
FDA Approves First Drug to Treat Rare Metabolic Disorder
Approval is for primary hyperoxaluria type 1, which causes recurrent kidney stones and loss of kidney function
PROGERIA RESEARCH FOUNDATION: First-Ever Treatment for Rare Rapid-Aging Disease Progeria Receives U.S. FDA Approval
The Progeria Research Foundation and Eiger BioPharmaceuticals Celebrate Historic Milestone with FDA Approval of Zokinvy™ (lonafarnib) for the Treatment of Progeria and Processing-Deficient Progeroid Laminopathies
BRAINEVER: Receives FDA Orphan Drug Designation for BREN-02, (human recombinant Engrailed 1) for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
BrainEver, a biotechnology company dedicated to the research and development of innovative therapies for the treatment of neurodegenerative diseases, announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to its product BREN-02
NICO.LAB: Ready to Revolutionize U.S. Stroke Care Following FDA Clearance
The U.S. Food and Drug Administration (FDA) has cleared StrokeViewer LVO, NICO.LAB's artificial intelligence powered solution in stroke care
FDA Announces Advisory Committee Meeting to Discuss Second COVID-19 Vaccine Candidate
The U.S. Food and Drug Administration has scheduled a meeting of its Vaccines and Related Biological Products Advisory Committee (VRBPAC) on Dec. 17 to discuss the request for emergency use authorization (EUA) for a COVID-19 vaccine from Moderna Inc.